Inventor · disambiguated record
Sunny Abraham
Also filed as: ABRAHAM SUNNY
16 granted patents·19 pending applications·64 citations·filing 2009–2024
92Inventor score
Files withVERTEX PHARMA11AMBIT BIOSCIENCES CORP9RECURIUM IP HOLDINGS LLC9KALYRA PHARMACEUTICALS INC2ZENO MAN INC2
Top patents by PatentIndex Score
35 records- 0195US12421251B2Cystic fibrosis transmembrane conductance regulator modulating agentsVERTEX PHARMA·Filed 2020·Granted Sep 23, 2025·5 cites·25 claims
- 0291US11261192B2Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-onesRECURIUM IP HOLDINGS LLC·Filed 2019·Granted Mar 1, 2022·5 cites·27 claims
- 0390US8618289B2RAF kinase modulator compounds and methods of use thereofABRAHAM SUNNY·Filed 2009·Granted Dec 31, 2013·22 cites·26 claims
- 0489US9320739B2RAF kinase modulator compounds and methods of use thereofAMBIT BIOSCIENCES CORP·Filed 2015·Granted Apr 26, 2016·6 cites·11 claims
- 0588US8969587B2RAF kinase modulator compounds and methods of use thereofAMBIT BIOSCIENCES CORP·Filed 2013·Granted Mar 3, 2015·8 cites·14 claims
- 0686US8349851B2JAK kinase modulating compounds and methods of use thereofAMBIT BIOSCIENCES CORP·Filed 2010·Granted Jan 8, 2013·9 cites·19 claims
- 0782US11098030B2EGFR inhibitor compoundsRECURIUM IP HOLDINGS LLC·Filed 2019·Granted Aug 24, 2021·1 cites·13 claims
- 0882US10525036B2Spirocyclic compoundsRECURIUM IP HOLDINGS LLC·Filed 2016·Granted Jan 7, 2020·2 cites·23 claims
- 0980US2024391924A1Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-onesRECURIUM IP HOLDINGS LLC·Filed 2024·Application pending·0 cites
- 1078US10053430B2RAF kinase modulator compounds and methods of use thereofAMBIT BIOSCIENCES CORP·Filed 2017·Granted Aug 21, 2018·1 cites·2 claims
- 1177US10513509B2EGFR inhibitor compoundsKALYRA PHARMACEUTICALS INC·Filed 2017·Granted Dec 24, 2019·1 cites·24 claims
- 1275US9730937B2RAF kinase modulator compounds and methods of use thereofAMBIT BIOSCIENCES CORP·Filed 2016·Granted Aug 15, 2017·1 cites·19 claims
- 1375US8927711B2JAK kinase modulating compounds and methods of use thereofAMBIT BIOSCIENCES CORP·Filed 2012·Granted Jan 6, 2015·2 cites·19 claims
- 1473US12049460B2EGFR inhibitor compoundsRECURIUM IP HOLDINGS LLC·Filed 2021·Granted Jul 30, 2024·0 cites·20 claims
- 1571US10493060B2Spirocyclic compoundsZENO ROYALTIES & MILESTONES LLC·Filed 2019·Granted Dec 3, 2019·1 cites·11 claims
- 1669US2022024939A1Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-onesRECURIUM IP HOLDINGS LLC·Filed 2021·Application pending·0 cites
- 1766US12410204B2Chiral synthesis of a tertiary alcoholRECURIUM IP HOLDINGS LLC·Filed 2020·Granted Sep 9, 2025·0 cites·19 claims
- 1863US2020268714A1Spirocyclic compoundsRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 1959US9308207B2JAK kinase modulating compounds and methods of use thereofAMBIT BIOSCIENCES CORP·Filed 2014·Granted Apr 12, 2016·0 cites·19 claims
- 2056US2023382924A1Modulators of cystic fibrosis transmembrane conductance regulatorVERTEX PHARMA·Filed 2021·Application pending·0 cites
- 2156US2023416275A1Modulators of cystic fibrosis transmembrane conductance regulatorVERTEX PHARMA·Filed 2021·Application pending·0 cites
- 2256US2023373974A1Modulators of cystic fibrosis transmembrane conductance regulatorVERTEX PHARMA·Filed 2021·Application pending·0 cites
- 2356US2023382925A1Modulators of cystic fibrosis transmembrane conductance regulatorVERTEX PHARMA·Filed 2021·Application pending·0 cites
- 2456US2023373939A1Modulators of cystic fibrosis transmembrane conductance regulatorVERTEX PHARMA·Filed 2021·Application pending·0 cites
- 2556US2023373935A1Modulators of cystic fibrosis transmembrane conductance regulatorVERTEX PHARMA·Filed 2021·Application pending·0 cites
- 2656US2023365587A1Modulators of cystic fibrosis transmembrane conductance regulatorVERTEX PHARMA·Filed 2021·Application pending·0 cites
- 2756US2024018161A1Modulators of cystic fibrosis transmembrane conductance regulatorVERTEX PHARMA·Filed 2021·Application pending·0 cites
- 2856US2023374038A1Modulators of cystic fibrosis transmembrane conductance regulatorVERTEX PHARMA·Filed 2021·Application pending·0 cites
- 2956US2024150377A1Modulators of cystic fibrosis transmembrane conductance regulatorVERTEX PHARMA·Filed 2021·Application pending·0 cites
- 3054US2023234956A1Methods of making wee1 inhibitor compoundsRECURIUM IP HOLDINGS LLC·Filed 2021·Application pending·0 cites
- 3151US2011269740A1Jak kinase modulating compounds and methods of use thereofAMBIT BIOSCIENCES CORP·Filed 2009·Application pending·0 cites
- 3247US2023192720A1Macrocyclic compoundsZENO MAN INC·Filed 2020·Application pending·0 cites
- 3346US2022144854A1Macrocyclic compoundsZENO MAN INC·Filed 2020·Application pending·0 cites
- 3437US2013035326A1Biaryl compounds and methods of use thereofAMBIT BIOSCIENCES CORP·Filed 2010·Application pending·0 cites
- 3536US2018201614A1Bicyclic compoundsKALYRA PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Sunny Abraham files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →